An open randomised study to assess the efficacy of gatifloxacin versus chloramphenicol for the treatment of uncomplicated typhoid fever in Kathmandu, Nepal

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN53258327

Enrollment

320

Registered

2006-04-11

Start date

2006-05-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Typhoid fever Infections and Infestations Typhoid fever

Interventions

Gatifloxacin versus Chloramphenicol. Added as of 20/09/2007: This trial was stopped temporarily in September 2006 at the request of the Nepal Health Research Council and Department of Drug Administra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Any patient with suspected uncomplicated enteric fever who gives consent.

Exclusion criteria

Exclusion criteria: 1. No consent 2. Pregnancy

Design outcomes

Primary

Measure	Time frame
Failure of treatment defined as the occurrence of any one of the following: 1. Persistent fever at day ten of treatment 2. Failure to clear completely the admission symptoms at day ten 3. Blood culture positive at day ten of treatment 4. Need for 'rescue' treatment with ceftriaxone 5. Culture confirmed relapse within 28 days of starting therapy 6. The development on treatment of any complication: 6.1 Clinically significant bleeding 6.2. Fall in the Glasgow Coma Score 6.3. Perforation of the gastrointestinal tract 6.4. Admission to hospital within 28 days of starting therapy	—

Measure

Time frame

Failure of treatment defined as the occurrence of any one of the following: 1. Persistent fever at day ten of treatment 2. Failure to clear completely the admission symptoms at day ten 3. Blood culture positive at day ten of treatment 4. Need for 'rescue' treatment with ceftriaxone 5. Culture confirmed relapse within 28 days of starting therapy 6. The development on treatment of any complication: 6.1 Clinically significant bleeding 6.2. Fall in the Glasgow Coma Score 6.3. Perforation of the gastrointestinal tract 6.4. Admission to hospital within 28 days of starting therapy

—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Nepal

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026